Dissecting respiratory disease heterogeneity through the genetics of diffusing capacity
Genome-wide association studies (GWASs) have allowed the robust and replicable identification of novel genomic regions associated with respiratory diseases. For instance, in chronic obstructive pulmonary disease (COPD), nearly all of the described genetic risk regions were not previously known to play a role in COPD pathogenesis [1–9]. However, where sample size is critical to discovery of new genetic risk regions in GWASs, large GWASs of lung function (and lung function extremes) in the general population have made great strides in describing the genetic risk regions contributing to the observed population variability in spirometry, and in risk of COPD [10–16]. Interestingly, the genetic risk regions contributing to the observed population variability of forced expiratory volume in 1 s (FEV1) and FEV1 to forced vital capacity (FVC) ratio can be aggregated into genetic risk scores which are predictive of COPD [14, 16, 17].
Publication date: May 2019Source: The Lancet Global Health, Volume 7, Issue 5Author(s): MyLinh Duong, Shofiqul Islam, Sumathy Rangarajan, Darryl Leong, Om Kurmi, Koon Teo, Kieran Killian, Gilles Dagenais, Scott Lear, Andreas Wielgosz, Sanjeev Nair, Viswanathan Mohan, Prem Mony, Rajeev Gupta, Rajesh Kumar, Omar Rahman, Khalid Yusoff, Johannes Lodewykus du Plessis, Ehimario U Igumbor, Jephat ChifambaSummaryBackgroundThe associations between the extent of forced expiratory volume in 1 s (FEV1) impairment and mortality, incident cardiovascular disease, and respiratory hospitalisations are unclear, and how these associations mi...
CONCLUSIONS: TGlittre-P reference equations were developed for females and males, with age being the most influential predictive variable in the test performed by children. PMID: 30992402 [PubMed - as supplied by publisher]
Authors: Obeidat M, Sadatsafavi M, Sin DD Abstract Chronic obstructive pulmonary disease (COPD) is defined based on a reduced ratio of forced expiratory volume in one second (FEV1 ) to forced vital capacity (FVC) on spirometry. However, within this definition, there is significant heterogeneity of pathophysiological processes that lead to airflow obstruction and variation in phenotypic manifestations across patients. Current pharmacological treatments are based on large randomised clinical trials that apply to an "average" patient. Precision health enables tailoring of treatment for each individual patien...
ConclusionsAlthough more apparent in asthma, it was revealed for the first time, that sex has a strong influence on the magnitude of dyspnea perception, both in asthma and COPD. Therefore, sex related dyspnea sensation should probably be included in clinical assessment and patient treatment.
CONCLUSIONS: Although more apparent in asthma, it was revealed for the first time, that sex has a strong influence on the magnitude of dyspnea perception, both in asthma and COPD. Therefore, sex related dyspnea sensation should probably be included in clinical assessment and patient treatment. PMID: 30953955 [PubMed - as supplied by publisher]
Conclusions: The prevention and management of COPD among coal miners deserves greater emphasis by rural health care delivery systems.
Conditions: Asthma; COPD Interventions: Device: AioCare; Device: Spirometer USB CPFS/D (MGC Diagnostics) Sponsors: National Institute for Tuberculosis and Lung Diseases, Poland; HealthUp Sp. z o.o. Completed
Clinical trials of COPD pharmacotherapy typically involve aging populations with moderate-to-severe COPD, but the latter is often diagnosed by spirometric criteria that are not age-appropriate across the continuum of lung function. We have therefore re-evaluated the clinical effect of combination therapy (salmeterol plus fluticasone) in moderate-to-severe COPD, using more age-appropriate spirometric criteria from the Global Lung Function Initiative (GLI) and trial data from Towards a Revolution in COPD Health (TORCH).